"TRK fusions are present in tumors with simple genomes lacking in concurrent drivers that may partially explain the tumor-agnostic efficacy of TRK inhibitors" - thus use the targeted therapy. #NTRK #PrecisionMedicine #Bayeremployee https://t.co/8OiYrzwm2r
https://t.co/EQ29RhWt4b TRK fusions (0.28% overall prevalence) involving 48 unique rearrangements and 17 cancer types. Associated with depletion of concurrent oncogenic drivers and low TMB, but CCR where cooccur with MSI-H.
RT @cancer_evolve: NTRK FUSIONS: these alterations are enriched in rare histologies and in cancers lacking other driver mutations with low…
NTRK FUSIONS: these alterations are enriched in rare histologies and in cancers lacking other driver mutations with low tumour mutational burden. An exception is colorectal cancer where NTRK fusions are correlated with MSI+ disease (as are RET fusions).…